Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. - Wikidata - awgldk - TriplyDB

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

http://www.wikidata.org/entity/Q44902909

about

Taxanes for adjuvant treatment of early breast cancer Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?Systemic treatment strategies for triple-negative breast cancer.Adjuvant treatment for older women with invasive breast cancer Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.Breast cancer (non-metastatic)Presentation and management of docetaxel-related adverse effects in patients with breast cancer Optimal approach in early breast cancer: Adjuvant and neoadjuvant treatment.Filling in the gaps: reporting of concurrent supportive care therapies in breast cancer chemotherapy trials.Febrile neutropenia rates with adjuvant docetaxel and cyclophosphamide chemotherapy in early breast cancer: discrepancy between published reports and community practice-a retrospective analysis The JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: pain and quality of life after primary surgery and before adjuvant treatment.Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Senior adult oncology: three cases of advanced cancer in patients of advanced age Changes in ovarian function in premenopausal women with breast cancer undergoing adjuvant TC (docetaxel and cyclophosphamide) chemotherapy during a brief period of amenorrhea around the last chemotherapy cycle.How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey.Bendamustine in Metastatic Breast Cancer: An Old Drug in New Design.Mammography Screening and Treatment of Breast Cancer in the Elderly Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer.Node-positive Breast Cancer: Which Are the Best Chemotherapy Regimens?Incidence of febrile neutropenia during adjuvant chemotherapy for breast cancer: a prospective study.Benefit risk assessment and update on the use of docetaxel in the management of breast cancer.A Canadian economic analysis of U.S. Oncology Adjuvant Trial 9735 Safety and tolerability of docetaxel, cyclophosphamide, and trastuzumab compared to standard trastuzumab-based chemotherapy regimens for early-stage human epidermal growth factor receptor 2-positive breast cancer The German SUCCESS C Study - The First European Lifestyle Study on Breast Cancer.Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.The role of HER-2 in Breast Cancer Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel/cyclophosphamide chemotherapy.The cost-utility of adjuvant chemotherapy using docetaxel and cyclophosphamide compared with doxorubicin and cyclophosphamide in breast cancer.Early breast cancer in the older woman.Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study.17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in rats Prevention and Treatment of Bone Metastases in Breast Cancer Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.

P2860

Q24242987-8DC9497D-BD74-440E-B424-35C48FD088D2 Q27025860-62D30A0A-B4A6-4D53-96DA-9B301DA5BCFD Q27691414-CDA6D362-2F36-4EAD-AB94-CD8174A6AAAF Q28066744-1EFDA3F4-3CEC-4974-857A-19AF9C219586 Q28477739-FC58A5A3-9D37-46A6-B0F5-C4D5667EE6D4 Q29994501-D9CD1B59-D1A2-44E1-AE8E-4E85E93E89AF Q30244077-311CD771-0223-4E28-BF63-6164DC075F6C Q30251429-17C23164-A7E5-4593-9BD1-0C1A624F9A90 Q33385774-E2561361-48FD-4523-A2BB-69B97F96A99A Q33388534-DC824CCA-3257-4A2A-ABB2-71FE9F6401C9 Q33427666-DD1D9C35-C9A0-4F87-BA36-046E2C3235FA Q33446778-ABEFAF7D-18BE-4A42-9EB6-E7BC4D19D445 Q33698286-195DFFB1-8FF4-4B10-A321-EEE8B9D69E10 Q33698446-E81C0FB2-CBC5-43CA-B8A7-595FBAF566B0 Q33785011-5F9E587F-1140-4F7B-A53D-9931FFFC3158 Q33789362-F51839C7-F2C3-4AFF-A525-D8180600D0AA Q33826701-0C1E1485-AE96-4A24-9B7D-37F1056BAB21 Q33827057-44FA182F-FD20-4567-95C1-04CD67857CC2 Q33928825-8F19A9D0-73E0-43A9-BDDA-C32DD9E6C6FA Q33955356-E54A72ED-0499-44D5-81F9-58DB9415F4EB Q33972876-BD737272-52E7-4B9A-AD7F-9FD77204CE57 Q34035471-21381B8D-FA9B-42CD-B736-FEFF65291C38 Q34096295-46D88905-4952-40B1-A931-B3140EF666D9 Q34096336-F2324E90-0434-485E-8371-548CDF0816F1 Q34184798-753369A3-7E74-427C-BEF5-94F421A566B0 Q34284278-02C3CE5C-212E-43E6-B6D2-9079108D6817 Q34293797-457F2A1A-ED40-4204-8D68-1374D50683A3 Q34379034-8CDE5210-1DBE-4612-97C0-8EE6C6B5FCF1 Q34761601-0F47F471-D14B-4FB1-A65D-D98445943689 Q34779671-F8A064D4-90B9-43D8-9BD6-4D0A80E65E6B Q34791139-147E7DA6-044E-4881-9DC3-1107BEC97CAD Q35047223-CE008BCC-3E6C-45B0-A502-DF432558B722 Q35068343-752BE8A6-AF93-4307-9175-A6738E195DA5 Q35237134-002CF44E-D4A9-45FC-9C0B-493DD1988188 Q35573019-708BE60E-2BED-44B6-A167-D1FD23E84E82 Q35584539-F4732FB5-B98F-4A5E-AB06-B34B761D2C1E Q35688776-AE013D6A-8B9E-446D-8127-B64EBEBA09A3 Q35746634-B15037E2-8F79-43AE-9865-13C2FFDBBCCD Q35750652-5E9107D9-385C-4627-B3B7-D19A451C6133 Q35786472-D9676937-9C72-4A4A-86A4-42D0427CCE08

P2860

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

http://www.wikidata.org/entity/Q44902909

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh

2006年學術文章

@zh-hant

name

Phase III trial comparing doxo ...... py for operable breast cancer.

@en

Phase III trial comparing doxo ...... py for operable breast cancer.

@nl

type

label

Phase III trial comparing doxo ...... py for operable breast cancer.

@en

Phase III trial comparing doxo ...... py for operable breast cancer.

@nl

prefLabel

Phase III trial comparing doxo ...... py for operable breast cancer.

@en

Phase III trial comparing doxo ...... py for operable breast cancer.

@nl

P1433

Q44902909-26BF0B00-2B1F-4BD0-9E97-B8CBA57DE420

P1476

Q44902909-D80ED8FC-EEB6-45BF-A4A9-A9C0E39CFA0E

P2093

Q44902909-190A9F24-A1DC-48E4-8C7F-945808371984

Q44902909-2D62EE06-A6A7-4FB7-A9C8-84B9EA5CDB2B

Q44902909-3E33F85A-5DFD-447E-8395-D08107D5F8F3

Q44902909-42D5F23E-9AEE-464A-AA04-E4DE349DE3A0

Q44902909-4644C210-3CA4-4A35-A6C5-6209D159D5F6

Q44902909-5ABC725F-82D3-44E4-8715-C2D42DD9EE1A

Q44902909-61BDE7F0-775A-4FE0-AEF2-F5FD1B82E02F

Q44902909-761CA71B-0FFF-4BEE-AA13-E44AD961BC1A

Q44902909-820BC8D6-C30D-4984-943D-A0012C6CCACB

Q44902909-8EF22351-0755-4571-9DFB-9E70553B82E6

P304

Q44902909-66678DD5-38A5-4769-A5E3-EFF8F4FCAE66

P31

Q44902909-356D49AB-8F5F-48EC-9B11-23117A269322

P356

Q44902909-1EBFFFEB-B475-4973-8789-0C0AF7107160

P407

Q44902909-37BCC779-111D-4A8B-95CC-B1501CB83660

P433

Q44902909-F5E7E63B-77B0-43F9-B1F7-5506679FAF68

P478

Q44902909-F2DE637F-4F90-4DF4-BFFB-1A92E218A55C

P577

Q44902909-288758F2-8C4A-4549-B5AF-E78AC345904A

P5875

Q44902909-936E37A2-30E8-4A0D-B9F1-7D585E5547BE

P698

Q44902909-E379276B-EAF8-4431-8340-3D806FBA12D7

P921

Q44902909-28203D31-E9F3-4992-818A-CD40B956D9C1

P356

JCO.2006.06.5391

P1433

Journal of Clinical Oncology

P1476

Phase III trial comparing doxo ...... py for operable breast cancer.

@en

P2093

Angel G Negron

http://www.w3.org/2001/XMLSchema#string

Donald A Richards

http://www.w3.org/2001/XMLSchema#string

Frankie Ann Holmes

http://www.w3.org/2001/XMLSchema#string

James H Bordelon

http://www.w3.org/2001/XMLSchema#string

Joanne L Blum

http://www.w3.org/2001/XMLSchema#string

John E Pippen

http://www.w3.org/2001/XMLSchema#string

John Sandbach

http://www.w3.org/2001/XMLSchema#string

Joyce A O'Shaughnessy

http://www.w3.org/2001/XMLSchema#string

Kristi A Boehm

http://www.w3.org/2001/XMLSchema#string

Kristi J McIntyre

http://www.w3.org/2001/XMLSchema#string

P304

5381-5387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.06.5391

http://www.w3.org/2001/XMLSchema#string

P407

P433

34

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6662482

http://www.w3.org/2001/XMLSchema#string

P698

17135639

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial